This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. The Natural History Studies Grants Program funds natural history studies that collect gather data on how rare diseases progress over time without treatment.
The cause is unknown, and there is currently no evidence stating whether surgical or non-surgical treatment is best for children with Perthes’ disease. This is a commonly used method, particularly when there is not a wealth of evidence to direct treatment. What is the NON-STOP project?
Kendal Chidwick NDARC’s Kendal Chidwick discusses the findings from a recently published study that examined how patterns of opioid agonist treatment medicines have changed over the past decade. Other changes around this time aimed at improving treatment accessibility included increased use of take-home doses and telehealth appointments.
In 2014, we wrote a blog post on CRISPR’s potential for correcting monogenetic diseases. Now, almost 10 years later, CRISPR’s potential for treatment is no longer an accurate descriptor; progress in clinical therapy is more fitting, so it is time to update our post.
Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. The MAA file in the E.U.
Physician blogs are a great way to get your physicians’ messages out to the public. Blog articles that include your physicians’ bylines and consumer-friendly, understandable language help position your team of physicians as thought-leaders in their fields of expertise.
Valentine We recently blogged about a new December 2024 draft guidance about accelerated approval (the December 2024 draft guidance). This blog post focuses on interpreting these new authorities with respect to timely conduct of confirmatory trials. Tobolowsky & Charles G. Raver & James E.
Advancing reduction of drug use as an endpoint in addiction treatment trials astewart Thu, 03/06/2025 - 09:59 Nora's Blog March 18, 2025 Image Getty Images/ SolStock This blog was also published in the American Society of Addiction Medicine (ASAM) Weekly on March 18, 2025.&
Various types of clinical studies play a pivotal role in ensuring the approval of life-saving medications and treatments. In this blog, we’re examining why participating in a clinical trial can be a rewarding experience for patients, and provide guidance on how potential volunteers can discover relevant studies.
Inhaled combination products (ICP) have emerged as a significant advancement in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. What regulatory division governs ICPs? ICPs are subject to rigorous regulatory scrutiny due to their complexity.
AUC represents the total response of a system to varying levels of a drug or treatment and can serve as a powerful curve quality control metric. AUC calculation: Area Under the Curve is now available as a default calculated parameter on all dose response (Hill Equation) protocols.
These differences not only shape tumor behavior but also impact the efficacy of therapeutic strategies, highlighting the need for tailored approaches in cancer treatment. Understanding and leveraging this variability through advanced models like co-culture systems is critical for developing effective, type-specific therapies.
Residential Treatment Compared With Outpatient Treatment Coupled With MOUD "Residential treatment is often considered the highest intensity of treatment for individuals with OUD [ 40 ], and may by particularly important for those with unstable housing, co-morbid mental health conditions, or high medical need [ 41 ].
Agonist Treatment for Cannabis Use Disorder "Cannabinoid agonist treatment is unlikely to be an approach relevant to all cannabis users seeking treatment, as evidenced by the large numbers of individuals who did not complete the study screening process, and the modest 12-week treatment retention rates.
50 years after founding, NIDA urges following science to move beyond stigma area Thu, 02/01/2024 - 11:20 Nora's Blog February 1, 2024 Image NIDA Image In 2024, NIDA celebrates its 50th anniversary. There was little in the way of effective prevention, and the only drug addiction treatment available was methadone.
Treatment for Methamphetamine Use "Methamphetamine is a highly addictive psychostimulant with evidence of neurotoxic properties ( 1 – 3 ) and is consistently ranked as one of the most harmful illicit substances—both to the person using and to society ( 4 , 5 ). 33.8) ( 18 )." 33.8) ( 18 )." Psychiatry 14:1123424. doi: 10.3389/fpsyt.2023.1123424
Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment "The findings revealed that exposures to MOUD, even if not continued throughout the six-month exposure period was associated with reduced risk of a fatal poisoning compared to non-MOUD forms of treatment and no treatment exposure.
Regardless of region, jail jurisdiction size, locality, or opioid overdose death rate, larger percentages of jail jurisdictions initiated behavioral or psychological treatment for OUD than initiated or continued MAT. "In Opioid Use Disorder Screening and Treatment in Local Jails, 2019. In states with 24.0 In states with fewer than 10.0
Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
Over the past two decades, substance use treatment admissions have increased among people aged 50 and over. Chronic pain is prevalent among older adults, and treatment for pain is less effective in this age group than it is in younger people; it negatively impacts quality of life and is a risk factor for cognitive decline and premature death.
The power of protective layers: Employers advancing whole-person health mfleming Fri, 10/06/2023 - 17:56 Nora's Blog October 11, 2023 This blog was originally posted on LinkedIn.com. Stigma against people with substance use disorders can keep them from seeking treatment.
In December 2023, FDA established the Genetic Metabolic Diseases Advisory Committee (also called “GeMDAC,” which we blogged about here ) to advise FDA regarding treatments for genetic metabolic diseases (i.e., those reviewed by the CDER Division of Rare Diseases and Medical Genetics).
Emergence of Methadone Maintenance Treatment in the US "Methadone emerged as a maintenance treatment modality for heroin dependence in the mid-1960s. Mark Parrino, added that opioid treatment programs (OTPs) came into existence because of a rejection by the medical community to treat this particular patient population. "By
Syringe Service Program Use and Substance Use Treatment "In this study, there was no indication that needle-exchange use was associated with increasing drug use. Our analysis also suggested that among heroin injectors, needle-exchange participation was wholly compatible with the goals of drug treatment. 1981 , Robins 1980 ).
SUD Treatment for Young People: Limited Availability and Costly "Using the Substance Abuse and Mental Health Services Administration’s treatment locator and search engine advertising data, we identified 160 residential addiction treatment facilities that treated adolescents with opioid use disorder as of December 2022.
Opioid Use Disorder Screening and Treatment in Local Jails in the US "At midyear 2019, fewer than two-thirds (63%) of local jail jurisdictions conducted opioid use disorder (OUD) screenings at intake and more than half (54%) of jail jurisdictions provided inmates medications to treat opioid withdrawal (figure 1). Maruschak, Todd D.
A prescription not issued in the usual course of professional treatment or in legitimate, authorized research is not a prescription within the meaning of the CSA and the pharmacist knowingly filling it, along with the prescriber issuing it, is subject to penalties. 21 U.S.C. § 829; 21 C.F.R. Complaint ¶ 58. Complaint ¶ 59.
BRAIN at 10: A View from the National Institute on Drug Abuse mfleming Wed, 09/25/2024 - 19:31 Nora's Blog October 1, 2024 By Nora Volkow, MD, Director, and Rita Valentino, Ph.D., Director, Division of Neuroscience and Behavior, NIDA This blog was originally posted on the The BRAIN Blog.
While there are treatment options, many patients will succumb to the disease, with a 5-year relative survival rate of 12%, per the American Cancer Society and the Surveillance, Epidemiology, and End Results Program. It was created to assist researchers and healthcare professionals better understand and treat malignant mesothelioma.
To address the fentanyl crisis, greater access to methadone Is needed area Mon, 07/22/2024 - 12:43 Nora's Blog July 29, 2024 By Nora D. Almost all (99%) of those retained in treatment achieved remission. Methadone may even be preferable for patients considered to be at high risk for leaving OUD treatment and overdosing on fentanyl.
This blog explores the process required for manufacturing a highly potent API for an ophthalmic indication, based on a case study involving loteprednol etabonate, a topical corticosteroid used to treat eye inflammations. When handling loteprednol etabonate, additional containment strategies were applied to reduce aerosolization.
ECAs have significant potential to save resources and accelerate access to innovative treatment. In a previous blog , our experts took a deep dive into the concept of ECAs, their acceptable use cases, and the current regulatory guidance.
This blog presents examples that demonstrate how AI can be used throughout the drug development process, with a specific focus on patient enrollment. Predicting clinical outcomes helps identify participants who would likely respond better to treatment and who might be at a higher risk.
Given that the median duration of prison stay was only 16 days, excess risk of infection-related hospitalization after release may also reflect people seeking treatment outside prison for infections that initially developed before or during incarceration ( Lloyd et al., 2014 ; Joudrey et al., dwf_admin Sat, 10/07/2023 - 14:42 Source Thomas D.
Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
Gibbs — It’s been over a year and a half since Over-the-Counter (“OTC”) hearing aids became legal, and it’s not clear that they’ve made the difference in hearing loss treatment that Congress anticipated. (FDA Koblitz & Jeffrey N. FDA once estimated that OTC hearing aids would save patients over $3000.)
It has been a regular feature of the blog to give a read on what FDA has been talking about, at least through the form of press releases. It is not always an easy task because the nature of FDA’s practice in this respect has evolved over time. Apologies for the misfire, but hopefully we are working more smoothly now.
The “cause of disease” often requires understanding the disease genetics and the “treatment” usually requires drugs. In this blog we will review how CRISPR technology has brought drug and genetic screens together and expedited the drug discovery pipeline.
Cost Benefit Analysis of Opioid Treatment, Syringe Service Programs, and Test & Treat "Although model projections can only provide estimates of health benefits and costs, such analyses can provide intuition around critical mechanisms and assumptions to inform decision making.
Unlocking the Secrets to Patenting Drug Combinations: Strategies and Challenges As a pharmaceutical professional, you know how crucial it is to stay ahead of the curve when it comes to patenting innovative treatments. In our latest blog post, we dive into the strategies and challenges of patenting drug combinations.
Clinical trials are the backbone of medical research, enabling the development of new treatments and therapies that can improve patient outcomes. In this blog, we will delve into the world of clinical trial contact center services and explore how they enhance the entire trial process, from recruitment to post-trial follow-up.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content